Blade Therapeutics is a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade has assembled a critical mass of fibrosis expertise and a top-tier leadership team and world-class network of advisors with unparalleled experience in anti-fibrotic drug R&D. Blade 's lead program is a small molecule inhibitor targeting an intracellular cysteine protease that has been shown to be associated with fibrosis across diverse indications. The Company anticipates entering the clinic with its lead development candidate in mid-2018. For its foundational programs, Blade is leveraging insights from Johns Hopkins University School of Medicine (Laboratory of Hal Dietz, M.D.) to discover new therapeutic approaches that can broadly modulate fibrosis, and thereby contribute to the treatment of diverse diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/18/17 | $45,000,000 | Series B |
Bristol-Myers Squibb Deerfield Management Company, L.P. MPM Capital Novartis Venture Funds Osage University Partners Pfizer Strategic Investments Group | undisclosed |
